EuroPCR 2023 |TAVR in Cardiogenic Shock

Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear.

The aim of this study was to assess events in patients undergoing TAVR with balloon expandable valves (SAPIEN 3 and SAPIEN 3 Ultra). 

Populations were matched with propensity score. Primary end point was inhospital all-cause mortality, at 30 days and one year, and major complications in the same period of time. 

Data from 4952 patients with cardiogenic shock were obtained. Mean age was 75.6 year with mean ejection fraction of 39.9%. observed complications were annulus rupture in 0.3%, aortic dissection in 0.2%, 0.4% coronary obstruction, 1% cardiac perforation, 0.2% devise embolization and 0.7% conversion to open surgery. 

Compared against the matched cohort with no cardiogenic shock, there was more inhospital mortality (9.9% vs 2.7%, P<0.0001), stroke (2.9% vs 1.5%; P<0.0001), vascular complications (2.3% vs 1.3%, P<0.0001) and major bleeding (2.5% vs 0.7%, P<0.0001). 

At one year, were was 29.7% mortality vs 22.6% in patients with no cardiogenic shock (HR 1.57, CI 95% 1.43-1.72, P<0.001). After multivariable analysis, predictors of mortality at 30 days were dialysis, pacemaker implantation, assisting device requirement, and peripheral vascular disease. 

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

The author concluded that TAVR was effective and safe in the context of cardiogenic shock with acceptable events at 30 days and one year. These outcomes observed in a registry should suggest “primary” TAVR as the best strategy for patients with aortic stenosis leading to cardiogenic shock. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Abhijeet Dhoble at Late Breaking Trials Sessions, EuroPCR 2023, May 16, 2023, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...